GlobalData has released its new PharmaPoint Drug Evaluation report, “Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.
Teva’s and Active Biotech’s laquinimod (ABR-215062) is a synthetic, once-daily, orally-administered immunomodulator under investigation for the treatment of RRMS. It is related to, but chemically distinct from, linomide (Roquinimex; Active Biotech); an experimental agent that had demonstrated some efficacy in the treatment of MS, but clinical testing was prematurely terminated because of serious cardiopulmonary toxicity.
- Overview of Multiple Sclerosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Laquinimod including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Laquinimod for the top ten countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India
REMAIN up to date with MS News and Education